@article{01910eca6d454958bfad85d21cce31ef,
title = "Management of Enteritis Associated With Tricohepatoenteric Syndrome due to SKIV2L Mutation Using the Combination of JAK1/2 Inhibition and Azathioprine.",
abstract = "Tricohepatoenteric syndrome is a rare genetic disorder caused by mutations in SKIV2L or TTC37. An upregulation of type 1 interferon signaling is associated with the SKIV2L variation. Introduction of Baricitinib as a JAK1/ 2 kinase inhibitor alongside traditional immunosuppressive agents successfully reduced the symptoms of enteritis by blocking the inflammogenic effects of type 1 interferonopathy in a case of tricohepatoenteric syndrome diagnosed in a 5-year-old boy. ",
author = "Jonathan Talbot and Wiskin, {Anthony E} and Marie Monaghan and Anu Goenka and Gillian Rice and Marion Roderick",
note = "Copyright {\textcopyright} 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.",
year = "2022",
month = nov,
doi = "10.1097/PG9.0000000000000264",
language = "English",
volume = "3",
pages = "e264",
journal = "JPGN reports",
issn = "2691-171X",
publisher = "Wolters Kluwer Health",
number = "4",
}